Total amount: € 0,00
HOW TO ORDER
A Journal on Endocrine System Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Minerva Endocrinologica 2009 December;34(4):273-9
Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients
Mirzaei K. 1,2, Hossein-Nezhad A. 2, Javad Hosseinzadeh-Attar M. 2, Jafari N. 1, Najmafshar A. 1, Mohammadzadeh N. 1, Larijani B. 2 ✉
1 Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Nutrition and Biochemistry, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran
AIM: We investigated the role of the -4689G/T promoter variant of the visfatin gene on serum visfatin concentration and biochemical markers in T2DM patient.
METHODS: In a cross-sectional study we recruited 93 patients with type 2 diabetes. Laboratory and anthropometric measurements were included FBG, OGTT, HbA1C, lipid Profile, fasting serum visfatin, fasting serum insulin, weight, height, Body Mass Index (BMI) and waist hip ratio (WHR). Genotyping for visfatin gene was performed by using the PCR-RFLP method.
RESULTS: Our findings showed significant differences in levels of low density lipoprotein (LDL) cholesterol, total cholesterol, high density lipoprotein (HDL) cholesterol and fasting serum insulin among various types of visfatin genotype (TT, GG, and GT). This study showed a significant correlation between circulating levels of visfatin and weight, BMI, hs-CRP and fasting insulin in TT genotype. But regarding GG genotype only fasting insulin had a significant correlation with circulating visfatin.
CONCLUSIONS: Visfatin genotypes may account for insulin resistance and levels of lipid profile that may cause by different visfatin expression between genotypes.